Krystof S Bankiewicz - JoVE Visualize

Showing results (81-90 of 114) with videos related to

Pageof 12

Sort By:

Gene Therapy|March 15, 2018

MR-guided delivery of AAV2-BDNF into the entorhinal cortex of non-human primatesAlan H Nagahara, Bayard R Wilson, Iryna Ivasyk, et al.

Neuroimage|December 20, 2008

Real-time MR imaging of adeno-associated viral vector delivery to the primate brainMassimo S Fiandaca, Vanja Varenika, Jamie Eberling, et al.

Neurosurgery|September 28, 2010

Qualitative imaging of adeno-associated virus serotype 2-human aromatic L-amino acid decarboxylase gene therapy in a phase I study for the treatment of Parkinson diseaseFrancisco Valles, Massimo S Fiandaca, Jamie L Eberling, et al.

Brain Research. Brain Research Protocols|September 27, 2005

Real-time visualization and characterization of liposomal delivery into the monkey brain by magnetic resonance imagingMichal T Krauze, Tracy R Mcknight, Yoji Yamashita, et al.

Nanomedicine (London, England)|February 6, 2014

Pharmacokinetics, tumor accumulation and antitumor activity of nanoliposomal irinotecan following systemic treatment of intracranial tumorsCharles O Noble, Michal T Krauze, Daryl C Drummond, et al.

Journal of Neurology, Neurosurgery, and Psychiatry|August 1, 2020

Data-driven evolution of neurosurgical gene therapy delivery in Parkinson's diseaseR Mark Richardson, Krystof S Bankiewicz, Chadwick W Christine, et al.

Annals of Neurology|February 26, 2019

Magnetic resonance imaging-guided phase 1 trial of putaminal AADC gene therapy for Parkinson's diseaseChadwick W Christine, Krystof S Bankiewicz, Amber D Van Laar, et al.

Human Gene Therapy|August 13, 2009

Safety evaluation of AAV2-GDNF gene transfer into the dopaminergic nigrostriatal pathway in aged and parkinsonian rhesus monkeysXiaomin Su, Adrian P Kells, Eric J Huang, et al.

Molecular Therapy. Methods & Clinical Development|July 14, 2016

Widespread AAV1- and AAV2-mediated transgene expression in the nonhuman primate brain: implications for Huntington's diseasePiotr Hadaczek, Lisa Stanek, Agnieszka Ciesielska, et al.

Molecular Therapy : the Journal of the American Society of Gene Therapy|August 12, 2022

Long-term safety of MRI-guided administration of AAV2-GDNF and gadoteridol in the putamen of individuals with Parkinson's diseaseMatthew T Rocco, Asad S Akhter, Debra J Ehrlich, et al.

Pageof 12

Showing results (81-90 of 114) with videos related to

Sort By:

Pageof 12

Gene Therapy|March 15, 2018

MR-guided delivery of AAV2-BDNF into the entorhinal cortex of non-human primatesAlan H Nagahara, Bayard R Wilson, Iryna Ivasyk, et al.

Neuroimage|December 20, 2008

Real-time MR imaging of adeno-associated viral vector delivery to the primate brainMassimo S Fiandaca, Vanja Varenika, Jamie Eberling, et al.

Neurosurgery|September 28, 2010

Qualitative imaging of adeno-associated virus serotype 2-human aromatic L-amino acid decarboxylase gene therapy in a phase I study for the treatment of Parkinson diseaseFrancisco Valles, Massimo S Fiandaca, Jamie L Eberling, et al.

Brain Research. Brain Research Protocols|September 27, 2005

Real-time visualization and characterization of liposomal delivery into the monkey brain by magnetic resonance imagingMichal T Krauze, Tracy R Mcknight, Yoji Yamashita, et al.

Nanomedicine (London, England)|February 6, 2014

Pharmacokinetics, tumor accumulation and antitumor activity of nanoliposomal irinotecan following systemic treatment of intracranial tumorsCharles O Noble, Michal T Krauze, Daryl C Drummond, et al.

Journal of Neurology, Neurosurgery, and Psychiatry|August 1, 2020

Data-driven evolution of neurosurgical gene therapy delivery in Parkinson's diseaseR Mark Richardson, Krystof S Bankiewicz, Chadwick W Christine, et al.

Annals of Neurology|February 26, 2019

Magnetic resonance imaging-guided phase 1 trial of putaminal AADC gene therapy for Parkinson's diseaseChadwick W Christine, Krystof S Bankiewicz, Amber D Van Laar, et al.

Human Gene Therapy|August 13, 2009

Safety evaluation of AAV2-GDNF gene transfer into the dopaminergic nigrostriatal pathway in aged and parkinsonian rhesus monkeysXiaomin Su, Adrian P Kells, Eric J Huang, et al.

Molecular Therapy. Methods & Clinical Development|July 14, 2016

Widespread AAV1- and AAV2-mediated transgene expression in the nonhuman primate brain: implications for Huntington's diseasePiotr Hadaczek, Lisa Stanek, Agnieszka Ciesielska, et al.

Molecular Therapy : the Journal of the American Society of Gene Therapy|August 12, 2022

Long-term safety of MRI-guided administration of AAV2-GDNF and gadoteridol in the putamen of individuals with Parkinson's diseaseMatthew T Rocco, Asad S Akhter, Debra J Ehrlich, et al.

Pageof 12